Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
1999-08-03
2002-06-11
Wortman, Donna (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S093600, C424S093100, C435S235100
Reexamination Certificate
active
06403098
ABSTRACT:
STATEMENT REGARDING FEDERALLY-SPONSORED R&D
Not applicable.
REFERENCE TO A MICROFICHE APPENDIX
Not applicable
1. Field of the Invention
The present invention is related to novel liquid and lyophilized formulations of rotaviruses useful as vaccines and methods for their preparation.
2. Background of the Invention
Rotaviruses (RV) cause acute gastroenteritis, a disease that requires hospitalization of infants and young children in developed countries, and a frequent cause of death in children less than 5 years of age in developing regions of the world. Studies in the United States, Australia, and Japan have demonstrated that between 34 and 63% of hospitalizations of children for acute diarrheal disease are associated with rotavirus infection. The incidence of hospitalization for rotavirus gastroenteritis in a health maintenance organization in the U.S. was estimated to be 222 per 100,000 in children from 13 to 24 months of age, and 362 per 100,000 in those less than one year. Infection with rotavirus was associated with 63% of all hospitalizations for acute diarrhea in this pediatric population. A review of mortality data in the U.S. from 1973 to 1983 indicated that 500 deaths per year occur in children less than 4 years old due to diarrheal diseases, and that 20 to 80% of excess winter deaths due to diarrhea in the U.S. are associated with rotavirus infections. Rotaviruses are also responsible for substantial proportion of the mortality associated with diarrheal diseases in third world countries. An effective rotavirus vaccine would therefore have a major impact on the health of children in both the developed and developing areas of the world.
Rotaviruses have an inner and outer capsid with a double-stranded RNA genome formed by eleven gene segments. Multiple serotypes have been defined by plaque reduction neutralization tests, and studies of reassortant viruses have demonstrated that two outer capsid proteins, VP7 and VP4, are the determinants of virus serotype. The VP7 protein is coded for by either gene segment 7, gene segment 8 or gene segment 9 of a particular human rotavirus. The location of the VP7 encoding gene may be determined for each specific rotavirus by conventional experimental methods. The VP4 protein is an 88,000 dalton major surface structural protein product of gene 4 of a rotavirus. Like VP7, it functions as a major serotype-specific antigen, operative in serum neutralization (SN) tests, capable of inducing serotype-specific neutralizing antibody, and capable in a mouse system of inducing serotype-specific immune protection against rotavirus disease. In some earlier references, the VP4 was referred to as VP3. After 1988, a change in nomenclature, resulted in the more proper reference to this protein as VP4.
Since the gene segments encoding the VP7 and VP4 proteins segregate independently, it has been proposed that serotyping nomenclature include both the G type, determined by VP7, and the P type, determined by VP4. Most human rotavirus infections in the U.S. are caused by viruses of G types 1, 2, 3, or 4, and P types 1, 2, or 3. However, other human rotavirus types, including for example, type G9, are more prevalent in Asia, Europe and certain third world countries.
A number of animal rotaviruses are attenuated in humans, and have been evaluated as potential live rotavirus vaccines, including the bovine serotype G6 WC3 rotavirus. The WC3 vaccine virus was shown to be immunogenic and non-reactogenic in infants, but was inconsistent in providing protective immunity against human rotavirus infection. It has been suggested that serotype-specific immunity is necessary to include consistent protection against rotavirus diarrhea.
There exists a need to the art for effective vaccines providing protective immunity against rotavirus infection and the severe clinical symptoms associated therewith.
For worldwide distribution of rotavirus vaccines, it is necessary to formulate vaccines such that they are stable under a variety of environmental conditions. Components used to stabilize vaccines are known. However, particular formulations of components useful to stabilize rotavirus vaccines must be determined experimentally. One object of the present invention is present formulations which stabilize rotavirus vaccines.
SUMMARY OF THE INVENTION
The present invention provides novel formulations of rotaviruses useful as vaccines and methods for their preparation.
REFERENCES:
patent: 5626851 (1997-05-01), Clark et al.
patent: 5750109 (1998-05-01), Clark et al.
patent: 5827534 (1998-10-01), Fasano
patent: 0 065 905 (1982-05-01), None
patent: 0 192 404 (1986-02-01), None
patent: WO 96/01651 (1996-01-01), None
Gajardo, et al., “Two Proline Residues Are Essential in the Calcium-Binding Activity of Rotavirus VP7 Outer Capsid Protein”, Journal of Virology, vol. 71, No. 3, Mar. 1997, pp. 2211-2216.
Ludert, et al., “Penetration and Uncoating of Rotaviruses in Cultered Cells”, Intervirology, vol. 27, pp. 95-101, 1987.
Shirley, et al., “The Influence of Divalent Cations on the Stability of Human Rotarvirus”, Archives of Virology, vol. 67, pp. 1-9, 1981.
Meng, et al., “Physicochemical Stability and Inactivation of Human and Simian Rotaviruses”, Applied and Environmental Microbiology, vol. 53, No. 4, pp. 727-730, 1987.
Willoughby, et al., “SA11 Rotavirus Is Specifically Inhibited by an Acetylated Sialic Acid”, The Journal of Infectious Diseases, vol. 161, pp. 116-119, 1990.
Fukudome, et al., “Comparison of Human, Simian and Bovine Rotaviruses for Requirement of Sialic Acid in Hemagglutination and cell Adsorption”, Virology, vol. 172, 99. 196-205, 1989.
Superti, et al., “Effect of Polyions on the Infectivity of SA-11 Rotavirus in LCC-MK2 Cells”, Comp. Immun. Microbiol. Infect. Dis., vol. 16, No. 1, pp. 55-62, 1993.
Garbag-Chenon, et al., “Reactogenicity and Immunogenicity of Rotavirus WC3 Vacine in 5-12-Month Old Infants”, Res. Virol., vol. 140, pp. 207-217, 1989.
Mendez, et al., “Binding to Sialic Acids Is Not an Essential Step for the Entry of Animal Rotaviruses to Epithelial Cells in Culture”, J. of Virology, vol. 67, No. 9, Sep. 1993, pp. 5253-5259.
Ducan, et al., “Comparative Analysis of Oral Delivery Systems For Live Rotavirus Vaccines”, J. of Controlled Release, vol. 41, pp. 237-247, 1996.
Ruiz, et al., “The Concentration of Ca2+ That Solybilizes Outer Capsid Proteins from Rotavirus Particles Is Dependent on the Strain”, Journal of Virology, vol. 70, No. 8, pp. 4877-4883, 1996.
Yolken, et al., “Intestinal Mucins Inhibit Rotavirus Replication in an Oligosaccharide-Dependent Manner”, The Journal of Infectious Disease, vol. 169, pp. 1002-1006, 1994.
Shahrabadi, et al., “Further Analysis of theRole of Calcium in Rotavirus Morphogenesis”, Virology, vol. 158, pp. 103-111, 1987.
Ward, et al., “Comparative Study on the Mechanisms of Rotavirus Inactivation oby Sodium Dodecyl Sulfate and Ethylenediaminetetraacetate”, Applied and Environmental Microbiology, vol. 39, No. 6, pp. 1148-1153, 1980.
Estes, et al., “Rotavirus Stability and Inactivation”, J. Gen. Virol., vol. 43, pp. 403-409, 1979.
Dormitzer, et al., “Calcium Chelation induces a Conformational Change in Recombinant HerpesSimplex Virus-1-Expressed Rotavirus VP7”, Virology, vol. 189, pp. 828-832, 1992.
Chen, et al., “Determinants of Rotavirus Stability and Density During CsCl Purification”, Virology, vol. 186, pp. 228-237, 1992.
Christy, et al., “Evaluation of a Bovine-Human Rotavirus Reassortant Vaccine in Infants”, Journal of Infectious Disease, vol. 168, pp. 1598-1599, 1993.
Kabayashi, et al., “Tetravalent Rhesus Rotavirus Vaccine in Young Infants”, Journal of Infectious Disease, vol. 170, pp. 1260-1263, 1994.
Ing, et al., “Immunogenicity of Tetravalent Rhesus Rotavirus Vaccine Adminsitered With Buffer and Oral Polio Vaccine”, AJDC, vol. 145, pp. 892-897, 1991.
Vesikari, et al., “Increased ‘Take’ Rate of Oral Rotavirus Vaccine in Infants After Milk Feeding”, The Lancet, pp. 700, 1984.
Borian, et al., “The Effect of Buffer on the Immune Response of Oral Rotavirus Vaccine”, Ped. Res., vol. 23, No. 982, pp. 365A, 1988.
Flores, et
Burke Carl J.
Volkin David B.
Merck & Co. , Inc.
Tribble Jack L.
Wortman Donna
Yablonsku Michael D.
LandOfFree
Rotavirus vaccine formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rotavirus vaccine formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rotavirus vaccine formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2955268